People | September 12, 2025
Lonza appoints Jason Berndt as Head of Group Operations
Maria Soler Nunez appointed as Chief Quality Officer
Maria Soler Nunez appointed as Chief Quality Officer
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Phase 3 data expected in the second half of 2024
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Subscribe To Our Newsletter & Stay Updated
